Inactive Instrument

Vincero Capital Corp.

VCO.P

CA9273191036

Vincero Capital Corp. Reports Earnings Results for the First Quarter Ended September 30, 2020

November 06, 2020 at 12:45 pm

Vincero Capital Corp. announced earnings results for the first quarter ended September 30, 2020. For the first quarter, the company announced net loss was CAD 30,423 compared to CAD 34,019 a year ago.

Latest news about Vincero Capital Corp.

Vincero Capital Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Vincero Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-23	CI
Certain Worldwide Rights of NewGen Therapeutics, Inc. completed the acquisition of Vincero Capital Corp. (TSXV:VCO.P) in a reverse merger transaction.	21-03-24	CI
Vincero Capital Corp. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-26	CI
Vincero Capital Corp. Reports Earnings Results for the First Quarter Ended September 30, 2020	20-11-06	CI
Vincero Capital Corp. Reports Earnings Results for the Full Year Ended June 30, 2020	20-10-02	CI
Vincero Capital Corp. Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-05-28	CI
Certain Worldwide Rights of NewGen Therapeutics, Inc. entered into a letter of intent to acquire Vincero Capital Corp. (TSXV:VCO.P) in a reverse merger transaction for CAD 6 million.	20-05-26	CI
Vincero Capital Corp. Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-02-20	CI
Vincero Capital Corp. has completed an IPO in the amount of CAD 0.5 million.	20-02-07	CI
Vincero Capital Corp. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-27	CI
Vincero Capital Corp. has filed an IPO in the amount of CAD 0.5 million.	19-09-11	CI

Chart Vincero Capital Corp.

Duration

Period

More charts

Company Profile

Rakovina Therapeutics, Inc., formerly Vincero Capital Corp., is a Canada-based company, which is engaged in developing cancer treatments based on DNA-damage response technologies. The Company's lead product candidate is kt-2000 Next Generation PARP-inhibitors. Its pipeline includes kt-3000 Dual Action DDR-inhibitors and kt-4000 DNA Damaging DDR-inhibitors. Its kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP). Its kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP. kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+180.51%	8.67B
CHURCHILL CAPITAL CORP VII	+2.29%	983M
APPLE ISPORTS GROUP, INC.	+41.91%	883M
PERELLA WEINBERG PARTNERS	+26.17%	825M
ARES ACQUISITION CORPORATION II	+1.92%	665M
E7 GROUP	+9.52%	664M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+9.17%	530M
CAPITOL INVESTMENT CORP. VII	-.--%	500M

Shell Companies